Celyad Oncology Reports First Half Year 2026 Results
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology (Euronext: CYAD) (“Celyad” or the “Company”), today announced its financial results for the first half year 2026 ended June 30, 2026. First Half 2026 financial review As of June 30, 2026, the Company’s cash position amounted to €0.1 million. Noteworthy is the event post balance sheet date (June 30), namely the capital increase with €0.5 million dated July 16, 2026 which has strengthened the cash position. After due c